Title:Anti-Adhesion Molecules: is Gut Specificity the Key for a Good Safety Profile?
Volume: 9
Issue: 4
Author(s): Patrick B Allen
Affiliation:
Keywords:
anti-TNF, adalimumab, infliximab, Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, natalizumab,
vedolizumab, alicaforsen,
Abstract: Inflammatory bowel diseases (IBD) are chronic relapsing and remitting disorders that have varying degrees of
severity. However multiple studies have confirmed that a large proportion of patients on maintenance treatment lose response
to anti-TNF therapy. This has led to increasing interest in the concept of ‘switching therapy out-of-class’ i.e. a nonanti-
TNF antibody when patients either fail to respond (primary non-response, develop secondary non-response) or do not
tolerate anti-TNF therapies. The most widely known and studied alternative class of antibodies therapies at present are the
selective adhesion molecule inhibitors. Several antibodies exist which constitute selection adhesion molecule inhibitors,
including Natalizumab, MLN-0002 (Vedolizumab) and ISIS 2302 (Alicaforsen) will be discussed in this review.
